Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial

Horn, Deborah B, Ryan, Donna H, Kis, Sanja Giljanovic, Alves, Breno, Mu, Yiming, Kim, Sin Gon, Aberle, Jens, Bain, Stephen C, Allen, Sheryl, Sarker, Elizabeth, Wu, Qiwei, Stefanski, Adam, Jouravskaya, Irina · 2025 · The Lancet

Abstract

BACKGROUND Obesity is a chronic disease that significantly contributes to type 2 diabetes and its complications. We aimed to evaluate orforglipron, an oral small-molecule (non-peptide) GLP-1 receptor agonist, for obesity treatment in adults with type 2 diabetes. METHODS This 72-week, phase 3, double-blind, placebo-controlled trial was conducted across 136 sites in ten countries. Participants with a BMI of 27 kg/m2 or higher and glycated haemoglobin (HbA1c) of 7-10% (53-86 mmol/mol) were randomly assigned (1:1:1:2) to once-daily orforglipron 6 mg, 12 mg, 36 mg, or placebo. The primary endpoint was the mean percent change in bodyweight from baseline to week 72. The treatment regimen estimand (using data from all randomly assigned participants, regardless of intercurrent events) was the primary estimand, with the efficacy estimand considered supportive. Safety was assessed in all patients who received at least one dose of study drug. This trial was registered at ClinicalTrials.gov (NCT05872620) and is completed. FINDINGS From June 5, 2023, to Feb 15, 2024, 2859 participants were screened, and 1613 (757 [46·9%] female) were randomly assigned, following a dose-escalation phase, to receive orforglipron 6 mg (n=329), 12 mg (n=332), 36 mg (n=322), or placebo (n=630), as an adjunct to lifestyle modification; 1444 (89·5%) completed the study. Baseline bodyweight was 101·4 kg (SD 22·5), BMI 35·6 kg/m2 (SD 6·6), and HbA1c 8·05% (SD 0·75; 64·4 mmol/mol [SD 8·2]). For the treatment regimen…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(25)02165-8

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 31 references

Research works printed but not linked: 1

  1. 2025, 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes—2025, Diabetes Care, 48, S167

Cited by

See all 70

Metadata

Authors
Horn, D. B., Ryan, D. H., Kis, S. G., Alves, B., Mu, Y., Kim, S. G., Aberle, J., Bain, S. C., Allen, S., Sarker, E., Wu, Q., Stefanski, A., & Jouravskaya, I.
Affiliations
  • Pennington Biomedical Research Center (US)
  • Centro Paulista de Investigação Clinica (BR)
  • Korea University (KR)
  • University Medical Center Hamburg-Eppendorf (DE)
  • Swansea University (GB)
  • Eli Lilly (United States) (US)
Corresponding author
Horn, Deborah B
Venue
The Lancet
Publisher
Elsevier BV
Published
2025-12
Volume
406
Issue
10522
Pages
2927-2944
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4416427646
Cited by
70
References
31
Citations by year
2026: 69 · 2025: 1
FWCI
47.38
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
orforglipron, GLP-1 receptor agonists, obesity, type 2 diabetes, weight loss, HbA1c, drug safety, adverse events, drug discontinuation, dose escalation
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Administration, Oral, Adult, Aged, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Obesity, Oxadiazoles, Body Mass Index, Treatment Outcome, Fluorine Compounds

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(25)02165-8
The paper
Horn, D. B., Ryan, D. H., Kis, S. G., Alves, B., Mu, Y., Kim, S. G., Aberle, J., Bain, S. C., Allen, S., Sarker, E., Wu, Q., Stefanski, A., & Jouravskaya, I. (2025). Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(25)02165-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.